About ImCheck Therapeutics
ImCheck Therapeutics is a Healthcare company based in Marseille (France) founded in 2015, and was acquired by Ipsen in December 2025. ImCheck Therapeutics is focused on immune system modulation innovation. It operates on a HealthTech model. ImCheck Therapeutics has raised $185.07 million across 6 funding rounds from investors including Pfizer, ARE and EQT. ImCheck Therapeutics offers products and services including ICT01 and ICT41. Its focus areas include Biotechnology and Immunotherapy.
Company details
ImCheck Therapeutics is engaged in developing next-generation immunotherapeutic antibodies. The company specializes in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. Solutions are targeted for the treatment of cancer, infectious diseases, and autoimmune conditions. Research and development efforts are centered on leveraging unique expertise in immunomodulation to address unmet medical needs across various therapeutic areas.
- Headquarters Marseille, France
- Stage Acquired
- SectorsHealthcare
- Website imchecktherapeutics.com
- Social LinkedIn X
- Acquired by Ipsen (Dec 2025)
Products & Services of ImCheck Therapeutics
ImCheck Therapeutics offers a comprehensive portfolio of products and services, including ICT01 and ICT41.
ICT01 is developed for treating Acute Myeloid Leukemia.
ICT41 is designed for immune system modulation therapy.
Funding Insights of ImCheck Therapeutics
ImCheck Therapeutics has successfully raised a total of $185.07M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $22.4 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $185.07M
- Total Rounds 6
- Last Round Grant — $22.4M
- First Round $21.8M
(May 2017)
- Investors Count 18
All 6 funding rounds of ImCheck Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2024 | $22.4M | Grant | – | – | |
| Jun 2022 | $103M | Series C | – | Earlybird, Andera Partners | |
| Sep 2020 | $7.1M | Series B | – | Pureos Bioventures | – |
| Dec 2019 | $53.17M | Series B | – | Bpifrance, Pfizer | |
| Aug 2019 | $2.28M | Grant | – | – | |
| May 2017 | $21.8M | Series A | – | Boehringer Ingelheim Venture Fund, Kurma Partners | – |
19 investors in total: 19 institutional.
Investors in ImCheck Therapeutics
ImCheck Therapeutics has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, ARE and EQT.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Earlybird is recognized as a venture capital investor focused on early-stage tech companies. | earlybird.com | Berlin, Germany | ||
Capital is provided to firms for growth, buyouts, and acquisitions. | 2001 | anderapartners.com | Paris, France | |
Biotech startups are funded through venture capital in life sciences. | 2009 | kurmapartners.com | Paris, France | |
Private equity and debt investments are managed across multiple sectors. | 1969 | eurazeo.com | Paris, France | |
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund. | boehringer-ingelheim-venture.com | |||
EQT is recognized as a global investment organization focused on value creation. | 1994 | eqtgroup.com | Stockholm, Sweden | |
Investments are made in early-stage healthcare startups. | wellington-partners.com | Munich, Germany | ||
Agent Capital is focused on healthcare venture capital investments. | agentcapital.com | Waltham, United States | ||
Venture capital is invested in innovative drug development companies. | pureosbio.com | Pfäffikon, Switzerland |
Investor details for ImCheck Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ImCheck Therapeutics
23 people are tracked at ImCheck Therapeutics (11 in leadership, 12 in team).
| Name | Role | Group |
|---|---|---|
Carla Cano | Lead Discovery Director | Leadership |
Pierre d'Epenoux | Chief Executive Officer | Leadership |
Claude Knopf | Chief Business Officer | Leadership |
Hans Henrik Chrois Christensen | CFO & COO | Leadership |
Diane Delpy-Sampson | Associate Director, program management | Leadership |
Cristina Ghirelli | Researh Operations Director | Leadership |
Patrick BRUNE | VP Oncology Program Director | Leadership |
Aude De Gassart | Preclinical research director | Leadership |
Sophie Agaugué | VP Preclinical Research | Leadership |
Charlotte Reynaud Desreux | Senior Director, QA & Compliance | Leadership |
Jessica Renaux | Director Of Clinical Operations | Leadership |
Floriane Grau | Business Controller | Team |
Maëlle MAIRESSE MIQUEU | Associate Project Lead | Team |
Florence ALCARAZ | Cytometry Platform Lead | Team |
Jaime Guillén Casas | Senior Research Scientist | Team |
Magali Colazet | R&D Scientist | Team |
Matthieu Delehaye | Finance Manager | Team |
Nabila Z. | Quality Assurance Manager | Team |
Nicolas Alvarez | Clinical Trial Manager | Team |
Marc Ambrosini | R&d Engineer | Team |
3 more people are available in the full profile.
Complete people profiles for ImCheck Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ImCheck Therapeutics
4 dated milestones of ImCheck Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded ImCheck Therapeutics is founded.
- Funding First funding round of $21.8M.
- Funding Latest funding round, Grant, of $22.4M.
- Exit Acquired by Ipsen.
Web traffic of ImCheck Therapeutics
The website of ImCheck Therapeutics (imchecktherapeutics.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▼ 30.5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Imcheck Therapeutics
Complete news archive for ImCheck Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ImCheck Therapeutics
ImCheck Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
ImCheck Therapeutics is headquartered in Marseille, France. It is registered at Marseille, Provence-alpes-cote D'azur, France.
ImCheck Therapeutics is a funded company, having raised a total of $185.07M across 6 funding rounds to date. The company's 1st funding round was a Series A of $21.8M, raised on May 2017.
ImCheck Therapeutics is engaged in developing next-generation immunotherapeutic antibodies. The company specializes in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. Solutions are targeted for the treatment of cancer, infectious diseases, and autoimmune conditions. Research and development efforts are centered on leveraging unique expertise in immunomodulation to address unmet medical needs across various therapeutic areas.
ImCheck Therapeutics offers ICT01 and ICT41.
Yes. ImCheck Therapeutics was acquired by Ipsen in December 2025.